Chemomab Therapeutics Ltd...

NASDAQ: CMMB · Real-Time Price · USD
0.94
0.04 (4.76%)
At close: Aug 15, 2025, 3:58 PM
0.92
-1.59%
After-hours: Aug 15, 2025, 04:12 PM EDT

Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis.

The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021.

Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. logo
Country IL
IPO Date Feb 12, 2019
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Adi Mor George

Contact Details

Address:
Building 7
Tel Aviv,
IL
Website https://www.chemomab.com

Stock Details

Ticker Symbol CMMB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534248
CUSIP Number 03280X102
ISIN Number US16385C1045
Employer ID 81-3676773
SIC Code 2834

Key Executives

Name Position
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director
Sigal Fattal CPA, M.B.A. Chief Financial Officer
Barbara Lindheim Consulting Vice President of Investor & Public Relations, Strategic Communications
Dr. David M. Weiner M.D. Interim Chief Medical Officer
Dr. Matthew B. Frankel M.B.A., M.D. Chief Medical Officer & Vice President of Drug Development
Jack Lawler Chief Development Officer

Latest SEC Filings

Date Type Title
Aug 14, 2025 6-K Filing
Aug 11, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 07, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 07, 2025 SCHEDULE 13G Filing
Jul 25, 2025 6-K Filing
Jul 25, 2025 424B5 Filing
Jul 01, 2025 6-K Filing
Jun 23, 2025 SCHEDULE 13D/A [Amend] Filing
May 27, 2025 6-K Filing
May 15, 2025 6-K Filing